Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Critically Ill
- Paralytic Ileus
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Consecutive enrolment parallel group in intervention group and placebo groupMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: The intervention was blinded to patients, nurse, investigators, and radiologistPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Prucalopride, a highly selective 5-HT4 receptor agonist, accelerates gastrointestinal transit which may reduce severity of ileus. Furthermore, there is no report of serious cardiac and neurological side effects. We aim to evaluate the efficacy of prucalopride as a prokinetic of choice on paralytic i...
Prucalopride, a highly selective 5-HT4 receptor agonist, accelerates gastrointestinal transit which may reduce severity of ileus. Furthermore, there is no report of serious cardiac and neurological side effects. We aim to evaluate the efficacy of prucalopride as a prokinetic of choice on paralytic ileus in critically ill patients.
Tracking Information
- NCT #
- NCT04190173
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sawangpong Jandee, Dr. Faculty of Medicine, Prince of Songkla University
Get Well Soon